After Allergan merger halt, vaccines a focus for Pfizer
Kalorama thinks Pfizer will continue to spotlight its vaccine business.
US Treasury regulation has dissuaded Pfizer from its planned merger with Ireland-based Allergan. The two companies agreed on Tuesday to terminate the deal. The tax inversion move would have benefited Pfizer's profitability and reintroduced the company to the dermatologics market. Pfizer will now consider business divestitures to boost its profits. Kalorama thinks that in addition to these steps, Pfizer will continue to spotlight its vaccine business, where it leads the pediatric category, according to its recent report.
"Continued patent expirations of important pharmaceutical products have also impacted Pfizer's revenues, necessitating an aggressive re-positioning of the company's business, which has resulted in the expansion of its vaccines operation," Kalorama Publisher Bruce Carlson said in a recent blog post.
Pfizer is the world's largest pediatric vaccine company with over 6 billion in revenues, according to Vaccines 2016: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others).
On a global basis, Pfizer employs more than 78,000 people worldwide. In 2015, Pfizer reported total global sales of $48.9 billion, up 6% from the prior year, as the company continues to optimize its operations though the acquisition of complementary businesses and divestiture of operations that no longer fit its core mandate.
Prevnar was FDA-approved for use in children in 2000 in the US, and is now approved in more than four dozen countries. The vaccine — pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein containing 4,6B,9V,14,18C,19F, and 23F) — targets the seven serotypes of pneumococcal bacteria most prevalent in the US, which are also among the most resistant to antibiotics and cause 80% of pneumococcal disease in infants. Pfizer has since phased out original Prevnar in favour of Prevnar 13.
In early 2015, Prevnar 13 received an indication expansion in Europe, to include the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance